Concepts (134)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Carboxylic Ester Hydrolases | 9 | 2017 | 52 | 3.050 |
Why?
|
| Anoikis | 9 | 2017 | 21 | 2.570 |
Why?
|
| Mitochondrial Proteins | 7 | 2017 | 107 | 2.480 |
Why?
|
| Cadherins | 3 | 2017 | 90 | 1.620 |
Why?
|
| Lung Neoplasms | 4 | 2016 | 358 | 1.430 |
Why?
|
| Repressor Proteins | 4 | 2016 | 249 | 1.070 |
Why?
|
| Gene Expression Regulation, Neoplastic | 7 | 2014 | 807 | 0.840 |
Why?
|
| Cell Transformation, Neoplastic | 5 | 2017 | 172 | 0.770 |
Why?
|
| Neoplasm Metastasis | 5 | 2016 | 219 | 0.740 |
Why?
|
| Cyclin D1 | 4 | 2007 | 43 | 0.700 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 2 | 2017 | 93 | 0.670 |
Why?
|
| Down-Regulation | 6 | 2017 | 435 | 0.520 |
Why?
|
| Apoptosis | 6 | 2013 | 1398 | 0.470 |
Why?
|
| Cell Proliferation | 5 | 2017 | 1198 | 0.460 |
Why?
|
| Tumor Suppressor Proteins | 2 | 2014 | 194 | 0.440 |
Why?
|
| Proto-Oncogene Proteins c-myc | 3 | 2007 | 54 | 0.430 |
Why?
|
| Adenocarcinoma | 1 | 2014 | 251 | 0.420 |
Why?
|
| Co-Repressor Proteins | 4 | 2016 | 16 | 0.420 |
Why?
|
| Cell Line, Tumor | 11 | 2014 | 2231 | 0.370 |
Why?
|
| Breast Neoplasms | 6 | 2012 | 1502 | 0.360 |
Why?
|
| Cisplatin | 2 | 2007 | 72 | 0.320 |
Why?
|
| Pancreatic Neoplasms | 2 | 2007 | 111 | 0.320 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2007 | 222 | 0.310 |
Why?
|
| Protein Kinase C | 1 | 2008 | 120 | 0.300 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2008 | 168 | 0.300 |
Why?
|
| NF-kappa B | 2 | 2007 | 339 | 0.290 |
Why?
|
| Antigens, CD | 2 | 2017 | 121 | 0.270 |
Why?
|
| RNA, Small Interfering | 3 | 2014 | 409 | 0.220 |
Why?
|
| Mice | 11 | 2014 | 5913 | 0.220 |
Why?
|
| Transcription, Genetic | 2 | 2016 | 578 | 0.210 |
Why?
|
| Transfection | 6 | 2012 | 523 | 0.200 |
Why?
|
| Humans | 16 | 2017 | 37093 | 0.200 |
Why?
|
| Extracellular Matrix | 3 | 2013 | 115 | 0.190 |
Why?
|
| Animals | 12 | 2014 | 15081 | 0.180 |
Why?
|
| Cell Line | 2 | 2017 | 1354 | 0.180 |
Why?
|
| Antineoplastic Agents | 4 | 2007 | 803 | 0.160 |
Why?
|
| Promoter Regions, Genetic | 2 | 2014 | 515 | 0.160 |
Why?
|
| Mitochondria | 2 | 2014 | 487 | 0.150 |
Why?
|
| Ribosomal Protein S6 Kinases, 90-kDa | 2 | 2008 | 22 | 0.150 |
Why?
|
| Genes, X-Linked | 2 | 2007 | 8 | 0.140 |
Why?
|
| Cell Differentiation | 2 | 2017 | 587 | 0.130 |
Why?
|
| Serpins | 2 | 2006 | 27 | 0.120 |
Why?
|
| Histone Deacetylases | 1 | 2014 | 56 | 0.120 |
Why?
|
| Tumor Burden | 1 | 2014 | 77 | 0.120 |
Why?
|
| Caspases | 1 | 2014 | 147 | 0.120 |
Why?
|
| Up-Regulation | 1 | 2016 | 513 | 0.120 |
Why?
|
| Gene Knockdown Techniques | 1 | 2014 | 173 | 0.120 |
Why?
|
| Epithelial Cells | 3 | 2013 | 384 | 0.120 |
Why?
|
| Neoplasms | 3 | 2011 | 1103 | 0.110 |
Why?
|
| Cell Movement | 2 | 2014 | 571 | 0.110 |
Why?
|
| Cell Survival | 2 | 2007 | 864 | 0.110 |
Why?
|
| Cell Adhesion | 3 | 2008 | 212 | 0.110 |
Why?
|
| Cell Nucleus | 1 | 2014 | 366 | 0.100 |
Why?
|
| Disease Progression | 2 | 2011 | 601 | 0.100 |
Why?
|
| Female | 8 | 2014 | 20969 | 0.100 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2008 | 623 | 0.090 |
Why?
|
| MAP Kinase Signaling System | 1 | 2011 | 169 | 0.090 |
Why?
|
| Mice, Inbred BALB C | 1 | 2011 | 661 | 0.090 |
Why?
|
| Disease Models, Animal | 1 | 2014 | 1371 | 0.080 |
Why?
|
| Genes, Tumor Suppressor | 2 | 2006 | 63 | 0.080 |
Why?
|
| Phosphorylation | 2 | 2008 | 928 | 0.080 |
Why?
|
| Integrins | 1 | 2008 | 51 | 0.080 |
Why?
|
| Cytoplasm | 1 | 2008 | 143 | 0.080 |
Why?
|
| Genes, myc | 1 | 2007 | 29 | 0.080 |
Why?
|
| Nuclear Proteins | 2 | 2007 | 307 | 0.080 |
Why?
|
| Neoplasm Invasiveness | 1 | 2008 | 251 | 0.070 |
Why?
|
| Chromosomes, Human, X | 1 | 2007 | 22 | 0.070 |
Why?
|
| DNA Fragmentation | 1 | 2007 | 92 | 0.070 |
Why?
|
| Membrane Proteins | 2 | 2008 | 517 | 0.070 |
Why?
|
| Mammary Neoplasms, Experimental | 1 | 2007 | 70 | 0.070 |
Why?
|
| Mice, Transgenic | 2 | 2005 | 617 | 0.070 |
Why?
|
| Urokinase-Type Plasminogen Activator | 1 | 2006 | 3 | 0.070 |
Why?
|
| Pancreatic Elastase | 1 | 2005 | 7 | 0.070 |
Why?
|
| Mammary Neoplasms, Animal | 1 | 2005 | 30 | 0.070 |
Why?
|
| Mice, Inbred Strains | 1 | 2005 | 116 | 0.070 |
Why?
|
| Prostatic Neoplasms | 2 | 2006 | 935 | 0.070 |
Why?
|
| Electrophoretic Mobility Shift Assay | 1 | 2005 | 53 | 0.070 |
Why?
|
| Receptors, Cell Surface | 1 | 2006 | 144 | 0.070 |
Why?
|
| Deoxycytidine | 1 | 2005 | 22 | 0.060 |
Why?
|
| Culture Media | 1 | 2005 | 90 | 0.060 |
Why?
|
| Models, Biological | 1 | 2008 | 677 | 0.060 |
Why?
|
| Carrier Proteins | 1 | 2007 | 305 | 0.060 |
Why?
|
| Lymphatic Vessels | 1 | 2004 | 6 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2005 | 152 | 0.060 |
Why?
|
| Cell Hypoxia | 1 | 2004 | 58 | 0.060 |
Why?
|
| Peptides, Cyclic | 1 | 2004 | 29 | 0.060 |
Why?
|
| Flow Cytometry | 1 | 2005 | 399 | 0.060 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2004 | 59 | 0.060 |
Why?
|
| Cell Cycle | 1 | 2005 | 326 | 0.060 |
Why?
|
| Osteolysis | 1 | 2003 | 2 | 0.060 |
Why?
|
| Melanoma | 1 | 2004 | 96 | 0.060 |
Why?
|
| Bone Neoplasms | 1 | 2003 | 45 | 0.050 |
Why?
|
| Protein Biosynthesis | 1 | 2003 | 133 | 0.050 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2005 | 1039 | 0.050 |
Why?
|
| Neovascularization, Pathologic | 1 | 2003 | 127 | 0.050 |
Why?
|
| Protein Binding | 1 | 2005 | 972 | 0.050 |
Why?
|
| Mice, SCID | 3 | 2008 | 150 | 0.050 |
Why?
|
| Immunohistochemistry | 3 | 2012 | 893 | 0.050 |
Why?
|
| Mice, Inbred C57BL | 1 | 2005 | 1609 | 0.050 |
Why?
|
| Cell Growth Processes | 2 | 2012 | 41 | 0.050 |
Why?
|
| Proteins | 1 | 2003 | 369 | 0.050 |
Why?
|
| Claudins | 2 | 2008 | 7 | 0.040 |
Why?
|
| Blotting, Western | 2 | 2008 | 859 | 0.030 |
Why?
|
| Cell Division | 2 | 2004 | 307 | 0.030 |
Why?
|
| Male | 3 | 2006 | 20025 | 0.030 |
Why?
|
| Muscular Dystrophies | 1 | 2008 | 2 | 0.020 |
Why?
|
| Ataxia | 1 | 2008 | 9 | 0.020 |
Why?
|
| Neutropenia | 1 | 2008 | 18 | 0.020 |
Why?
|
| Syndrome | 1 | 2008 | 74 | 0.020 |
Why?
|
| Receptors, CXCR4 | 1 | 2008 | 69 | 0.020 |
Why?
|
| Fetal Development | 1 | 2008 | 29 | 0.020 |
Why?
|
| Retinoblastoma-Binding Protein 7 | 1 | 2007 | 1 | 0.020 |
Why?
|
| Oncogene Proteins | 1 | 2007 | 21 | 0.020 |
Why?
|
| Fibrinolysin | 1 | 2006 | 8 | 0.020 |
Why?
|
| Receptors, Urokinase Plasminogen Activator | 1 | 2006 | 10 | 0.020 |
Why?
|
| Focal Adhesions | 1 | 2006 | 15 | 0.020 |
Why?
|
| Breast | 1 | 2007 | 135 | 0.020 |
Why?
|
| DNA, Complementary | 1 | 2005 | 191 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2005 | 195 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2008 | 933 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 2006 | 515 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2005 | 306 | 0.020 |
Why?
|
| Transplantation, Heterologous | 1 | 2004 | 90 | 0.020 |
Why?
|
| Collagen Type I | 1 | 2003 | 30 | 0.010 |
Why?
|
| Gene Expression Profiling | 1 | 2007 | 626 | 0.010 |
Why?
|
| Mice, Nude | 1 | 2004 | 337 | 0.010 |
Why?
|
| Neoplasm Transplantation | 1 | 2003 | 122 | 0.010 |
Why?
|
| Cell Cycle Proteins | 1 | 2005 | 229 | 0.010 |
Why?
|
| Cell Death | 1 | 2004 | 267 | 0.010 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2003 | 201 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2007 | 1207 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 2003 | 502 | 0.010 |
Why?
|
| Cattle | 1 | 2003 | 477 | 0.010 |
Why?
|
| Time Factors | 1 | 2003 | 1742 | 0.010 |
Why?
|